2. Search Result
Search Result
Results for "

Pathway+Inhibitors

" in MedChemExpress (MCE) Product Catalog:

162

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

7

Peptides

6

Inhibitory Antibodies

36

Natural
Products

5

Isotope-Labeled Compounds

1

Click Chemistry

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-11006
    KU-57788
    40+ Cited Publications

    NU7441

    		 DNA-PK Cancer
    KU-57788 (NU7441) is a highly potent and selective DNA-PK inhibitor with an IC50 of 14 nM. KU-57788 is an NHEJ pathway inhibitor. KU-57788 also inhibits PI3K and mTOR with IC50s of 5.0 and 1.7 μM, respectively .
    KU-57788
  • HY-10440
    Vismodegib
    50+ Cited Publications

    GDC-0449

    		 Hedgehog Autophagy Neurological Disease Inflammation/Immunology Cancer
    Vismodegib (GDC-0449) is a BBB-permeable and orally active hedgehog pathway inhibitor with an IC50 of 3 nM. Vismodegib also inhibits P-gp, ABCG2 with IC50 values of 3.0 μM and 1.4 μM, respectively .
    Vismodegib
  • HY-16724
    Indoximod
    10+ Cited Publications

    1-Methyl-D-tryptophan; NLG-8189

    		 Indoleamine 2,3-Dioxygenase (IDO) Cancer
    Indoximod (1-Methyl-D-tryptophan) is an orally active indoleamine 2,3-dioxygenase (IDO) pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR. Indoximod is an immunometabolic adjuvant used for the research of cancer .
    Indoximod
  • HY-158102
    Rinzimetostat
    1 Publications Verification

    ORIC-944

    		 Histone Methyltransferase Cancer
    Rinzimetostat (ORIC-944) is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). Rinzimetostat is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer.
    Rinzimetostat
  • HY-18777
    KC7F2
    15+ Cited Publications

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    KC7F2 is a potent hypoxia inducible factor-1 (HIF-1) pathway inhibitor with an IC50 of 20 μM in LN229-HRE-AP cells, and with potential as a cancer therapy agent .
    KC7F2
  • HY-129390
    Orelabrutinib
    3 Publications Verification

    ICP-022

    		 Btk Cancer
    Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK .
    Orelabrutinib
  • HY-13968
    JW 55
    5 Publications Verification

    		 PARP Cancer
    JW 55 is a potent and selective β-catenin signaling pathway inhibitor, which functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2). JW 55 decreases auto-PARsylation of TNKS1/2 in vitro with IC50s of 1.9 μM and 830 nM respectively.
    JW 55
  • HY-108361
    CCG-203971
    2 Publications Verification

    		 Ras Inflammation/Immunology Cancer
    CCG-203971 is a second-generation Rho/MRTF/SRF pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC50 =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC50 of 4.2 μM. Potential anti-metastasis Agent .
    CCG-203971
  • HY-N6069
    Raspberry ketone glucoside
    1 Publications Verification

    		 Interleukin Related JAK STAT Inflammation/Immunology
    Raspberry ketone glucoside is a melanogenesis inhibitor. Raspberry ketone glucoside inhibits melanogenesis by activating the IL6/JAK1/STAT3 pathway, inhibiting the transcriptional activity of MITFa, and its downstream expression levels of the TYR and TYRP1a genes. Raspberry ketone glucoside shows remarkable whitening activity on both B16F10 cells in vitro and zebrafish model in vivo .
    Raspberry ketone glucoside
  • HY-P99725
    Marstacimab

    PF-06741086

    		 Thrombin Tissue Factor Pathway Inhibitor (TFPI) Metabolic Disease
    Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia .
    Marstacimab
  • HY-145927
    NXP800
    3 Publications Verification

    CCT361814

    		 HSP Cancer
    NXP800 (CCT361814) is a potent and orally active heat shock factor 1 (HSF1) pathway inhibitor. NXP800 has the potential for cancer research .
    NXP800
  • HY-18770B
    Navoximod
    10+ Cited Publications

    GDC-0919; NLG-​919

    		 Indoleamine 2,3-Dioxygenase (IDO) Cancer
    Navoximod (GDC-0919; NLG-?919) is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.
    Navoximod
  • HY-B1104
    Indoprofen

    (±)-Indoprofe

    		 Akt AMPK NF-κB p38 MAPK Inflammation/Immunology
    Indoprofen ((±)-Indoprofe) activates AKT-AMPK signaling pathway, inhibits NF-κB/MAPK signaling pathway. Indoprofen exhibits anti-inflammatory and immunomodulatory activities. Indoprofen is orally active .
    Indoprofen
  • HY-139553
    Zunsemetinib

    ATI-450; CDD-450

    		 MAPKAPK2 (MK2) Inflammation/Immunology
    Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .
    Zunsemetinib
  • HY-111432
    CCG-232601

    		Ras Others
    CCG-232601 (compound 8f) is a potent and orally active Rho/MRTF/SRF transcriptional pathway inhibitor. CCG-232601 inhibits the development of Bleomycin-induced dermal fibrosis in mice. CCG-232601 has the potential for the research of antifibrotic for systemic scleroderma .
    CCG-232601
  • HY-121750
    CCG-222740
    1 Publications Verification

    		 Ras ROCK Cancer
    CCG-222740 is an orally active and selective Rho/myocardin-related transcription factor (MRTF) pathway inhibitor . CCG-222740 is also a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 effectively reduces fibrosis in skin and blocks melanoma metastasis .
    CCG-222740
  • HY-107553
    Chetomin
    1 Publications Verification

    		 HSP Apoptosis Cancer
    Chetomin, an active component of Chaetomium globosum, is a heat shock protein 90/hypoxia-inducible factor 1 alpha (Hsp90/HIF1α) pathway inhibitor. Chetomin is a potent, nontoxic non-small cell lung cancer cancer stem cells (NSCLC CSC)-targeting molecule .
    Chetomin
  • HY-110247
    TRAF-STOP inhibitor 6877002
    4 Publications Verification

    		 TNF Receptor NF-κB Cardiovascular Disease Inflammation/Immunology
    TRAF-STOP inhibitor 6877002 is a selective CD40-TRAF6 interaction inhibitor. TRAF-STOP inhibitor 6877002 exerts anti-atherosclerotic activity by blocking the CD40-TRAF6 signaling pathway, inhibiting classical monocyte activation, leukocyte recruitment, and macrophage activation and migration. TRAF-STOP inhibitor 6877002 reduces the phosphorylation levels of signaling intermediates in the canonical NF-κB pathway .
    TRAF-STOP inhibitor 6877002
  • HY-164254
    Cardiomyocyte proliferation promoting agent-1

    (E/Z)-GA-002

    		 Large Tumor Suppressor (LATS) YAP Cardiovascular Disease Inflammation/Immunology Cancer
    Cardiomyocyte proliferation promoting agent-1 ((E/Z)-GA-002), which is an E/Z mixture, is a cardiomyocyte proliferation promoter. GA-002 (single E configuration) is a kinase inhibitor for LATS1 and LATS2, with its IC50 values being 3.93 nM and 3.87 nM respectively. GA-002 can induce the expression of genes regulated by the Hippo pathway, inhibit the phosphorylation of YAP/TAZ, and induce the nuclear translocation of YAP .
    Cardiomyocyte proliferation promoting agent-1
  • HY-13307
    JK184
    2 Publications Verification

    		 Hedgehog Cancer
    JK184 is a potent Hedgehog (Hh) pathway inhibitor with IC50 of 30 nM in mammalian cells.
    JK184
  • HY-100790
    Ciliobrevin A
    3 Publications Verification

    HPI-4

    		 Hedgehog Cancer
    Ciliobrevin A (HPI-4) is a hedgehog (Hh) signaling pathway inhibitor with median inhibitory concentration (IC50) less than 10 μM .
    Ciliobrevin A
  • HY-B1787
    Sulindac sulfone

    		mTOR Drug Metabolite Cancer
    Sulindac sulfone is an mTORC1 pathway inhibitor and a metabolite of Sulindac. Sulindac sulfone inhibits colon cancer cell growth and induces cell cycle arrest. Sulindac sulfone is used in cancer research .
    Sulindac sulfone
  • HY-115449
    Chromeceptin
    2 Publications Verification

    94G6

    		 IGF-1R Akt mTOR Cancer
    Chromeceptin (94G6) is an IGF signaling pathway inhibitor. Chromeceptin suppresses IGF2 expression at mRNA and protein levels in hepatocyte and HCC cells. Chromeceptin inhibits the phosphorylation levels of AKT and mTOR .
    Chromeceptin
  • HY-138537
    NF-κB-IN-1
    3 Publications Verification

    		 IKK Cancer
    NF-κB-IN-1, a 4-arylidene crucumin analogue, is a potent NF-κB signaling pathway inhibitor. NF-κB-IN-1 directly inhibits IKK to block NF-κB activation. NF-κB-IN-1 effectively inhibits the viability of lung cancer cells and attenuates the clonogenic activity of A549 cells .
    NF-κB-IN-1
  • HY-P5275
    Tripeptide-41

    CG-Lipoxyn

    		 NF-κB Histone Demethylase Metabolic Disease
    Tripeptide-41 (CG-Lipoxyn) is a signal peptide. Tripeptide-41 activates the NF-kB signaling pathway, inhibits the expression of C/EBP and increases cAMP. Tripeptide-41 is an important intracellular signaling factor that causes lipolysis by promoting the hydrolysis of lipids into triglycerides. Tripeptide-41 can be used in cosmetics that targets fat accumulation .
    Tripeptide-41
  • HY-N1399
    Androsin

    		AMPK PI3K Autophagy Metabolic Disease Inflammation/Immunology
    Androsin is an active compound isolated from Picrorhiza Kurroa Royle ex Benth. Androsin activates AMPKα/PI3K/Beclin1/LC3 signaling pathway, inhibits SREBP1c/FASN signaling pathway. Androsin can be used in research of asthma and non-alcoholic fatty liver disease (NAFLD). Androsin is orally active .
    Androsin
  • HY-121537
    CAY10404

    		COX Akt Apoptosis Neurological Disease Inflammation/Immunology Cancer
    CAY10404 is a potent and selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 1 nM and a selectivity index (SI; COX-1 IC50/COX-2 IC50) of >500000. CAY10404 is a potent PKB/Akt and MAPK signaling pathways inhibitor and induces apoptosis in non-small cell lung cancer (NSCLC) cells. CAY10404, a diarylisoxazole, has good analgesic, anti-inflammatory, and anti-cancer activities .
    CAY10404
  • HY-N8102
    Echinocystic acid 28-O-β-D-glucoside

    		Transmembrane Glycoprotein Others Cardiovascular Disease
    Echinocystic acid 28-O-β-D-glucoside is a metabolite of Echinocystic acid by microbial oxidation and glucosidation. Echinocystic acid 28-O-β-D-glucoside is a tissue factor pathway inhibitor, with an IC50 of 10.61 nM .
    Echinocystic acid 28-O-β-D-glucoside
  • HY-N7674
    Angoline
    3 Publications Verification

    		 Interleukin Related STAT Cancer
    Angoline is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation .
    Angoline
  • HY-146195
    MAPK-IN-1
    4 Publications Verification

    		 Toll-like Receptor (TLR) p38 MAPK JNK ERK Cholinesterase (ChE) Neurological Disease Inflammation/Immunology
    MAPK-IN-1 (Compound 2) is a MAPK signaling pathway inhibitor. MAPK-IN-1 exhibits AChE inhibitory activity with an IC50 of 23.84 μM. MAPK-IN-1 shows anti-neuroinflammatory and neuroprotective activity and can be used for Alzheimer's disease research .
    MAPK-IN-1
  • HY-136541
    YB-0158
    2 Publications Verification

    Wnt pathway inhibitor 2

    		 Wnt Apoptosis Cancer
    YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities .
    YB-0158
  • HY-112440
    HZX-02-059

    Methuosis inducer 1

    		 Microtubule/Tubulin NF-κB MDM-2/p53 PI3K Akt c-Myc Cancer
    HZX-02-059 is a potent methuosis inducer and dual-target PIKfyve/tubulin inhibitor with anticancer activity. Methuosis mainly disrupts the balance of endocytosis and exocytosis, forming a large number of vesicles and inducing cell death. HZX-02-059 also induces cell vacuolization, promotes apoptosis, downregulates the p53 pathway, inhibits PI3K/AKT phosphorylation, and inhibits c-Myc and NF-κB transcription .
    HZX-02-059
  • HY-153750
    Wnt pathway inhibitor 3

    		Wnt Cancer
    Wnt pathway inhibitor 3 is a potent wnt inhibitor with an IC50 value of 45 nM. Wnt pathway inhibitor 3 shows antiproliferative activity .
    Wnt pathway inhibitor 3
  • HY-137454
    Teplinovivint
    2 Publications Verification

    		 Wnt β-catenin Inflammation/Immunology
    Teplinovivint is a potent wnt/β-catenin signaling pathway inhibitor. Teplinovivint has anti-inflammatory activity and has the potential for tendinopathy research .
    Teplinovivint
  • HY-117229
    Sonidegib metabolite M48

    		Drug Metabolite Cancer
    Sonidegib metabolite M48 is the main circulating metabolite of Sonidegib. Sonidegib is a hedgehog pathway inhibitor. M48 showed a much longer Tmax (60 h) than Sonidegib .
    Sonidegib metabolite M48
  • HY-15398C
    3-epi-Vitamin D3

    Epicholecalciferol

    		 Hedgehog Cancer
    3-epi-Vitamin D3 (Epicholecalciferol) (Compound 4), a Vitamin D3 analogue, is a Hedgehog pathway inhibitor with an IC50 of 39.2 μM measured in U87MG cells .
    3-epi-Vitamin D3
  • HY-160709
    Wnt/β-catenin-IN-2

    		Wnt β-catenin Cancer
    Wnt/β-catenin-IN-2 (Compound 3235-0367) is a Wnt/β-catenin signaling pathway inhibitor, with IC50 and KD values of 7.1 and 2.5 μM, respectively. Wnt/β-catenin-IN-2 can be used for the research of cancer .
    Wnt/β-catenin-IN-2
  • HY-158102A
    Rinzimetostat TFA
    1 Publications Verification

    ORIC-944 TFA

    		 Histone Methyltransferase Cancer
    Rinzimetostat (ORIC-944) TFA is the TFA salt form of ORIC (HY-158102). Rinzimetostat TFA is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). Rinzimetostat TFA is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer .
    Rinzimetostat TFA
  • HY-142699
    SSTR4 agonist 2

    		Somatostatin Receptor Inflammation/Immunology
    SSTR4 agonist 2 is a potent agonist of somatostatin receptor subtype 4 (SSTR4). SSTR4 pathway inhibits nociceptive and inflammatory processes. SSTR4 agonist 2 has the potential for the research of medical disorders related to SSTR4 (extracted from patent WO2014184275A1, compound 107) .
    SSTR4 agonist 2
  • HY-113965
    CUR61414
    1 Publications Verification

    		 Hedgehog Smo Apoptosis Inflammation/Immunology
    CUR61414 is a novel, potent and cell permeable Hedgehog signaling pathway inhibitor (IC50 =100-200 nM). CUR61414 is a small-molecule aminoproline class compound and selectively binds to smoothened (Smo) with a Ki value of 44 nM. CUR-61414 can induce apoptosis in cancer cells without affecting neighboring non-tumor cells .
    CUR61414
  • HY-119966
    CCT036477

    		Wnt β-catenin PPAR CDK Cancer
    CCT036477 is a Wnt/β-catenin pathway inhibitor. CCT036477 blocks transcription at β-catenin without altering its levels. CCT036477 inhibits proliferation of various cancer cells, development of embryos, and expression of Wnt target genes (PPARδ, Cyclin D1, TCF4, and ID2) .
    CCT036477
  • HY-153480A
    ARC19499 sodium
    1 Publications Verification

    BAX499 sodium

    		 Factor Xa Factor VIIa Tissue Factor Pathway Inhibitor (TFPI) Others
    ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
    ARC19499 sodium
  • HY-168328
    FKK6

    		NF-κB Interleukin Related Inflammation/Immunology
    FKK6 is a selective agonist for pregnane X receptor (PXR) with an EC50 of 1.2 µM. FKK6 exhibits good affinity with plasma proteins, and good metabolic metabolism in human microsomes. FKK6 inhibits PXR-related NF-κB signaling pathway, inhibits the expression of inflammatory factors, and exhibits anti-inflammatory activity against DSS (HY-116282)-induced colitis in mouse model .
    FKK6
  • HY-144765
    NF-κB-IN-4
    1 Publications Verification

    		 NF-κB Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    NF-κB-IN-4 (compound 17) is a potent NF-κB pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research .
    NF-κB-IN-4
  • HY-U00460
    3,6-DMAD hydrochloride
    1 Publications Verification

    		 IRE1 Cancer
    3,6-DMAD hydrochloride, an acridine derivative, is a potent IRE1α-XBP1s pathway inhibitor. 3,6-DMAD hydrochloride promotes IL-6 secretion via the IRE1α-XBP1s pathway. 3,6-DMAD hydrochloride inhibits IRE1α oligomerization and endoribonuclease (RNase) activity. 3,6-DMAD hydrochloride can be used for research of cancer .
    3,6-DMAD hydrochloride
  • HY-163475
    CXCL-CXCR1/2-IN-1
    1 Publications Verification

    		 CXCR Cancer
    CXCL-CXCR1/2-IN-1 is an orally active ELR +CXCL-CXCR1/2 pathway inhibitor with an EC50 of 42.7 nM for CXCR2 . CXCL-CXCR1/2-IN-1 shows anticancer and antiangiogenic effects .
    CXCL-CXCR1/2-IN-1
  • HY-P991114
    Adezkibart

    		FLT3 Inflammation/Immunology
    Adezkibart is a human monoclonal antibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to FLT3LG to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases .
    Adezkibart
  • HY-P10436
    Braftide

    		Raf Cancer
    Braftide is an allosteric inhibitor for BRAF kinase by targeting the dimer interface of BRAF kinase and inhibiting the formation of BRAF dimers. Braftide inhibits wild-type BRAF and oncogenic BRAF G469A with IC50 of 364 nM and 172 nM, respectively. Braftide inhibits MAPK signaling pathway, inhibits proliferation of KRAS mutant tumor cells (EC50 is 7.1 and 6.6 μM, for HCT116 and HCT-15), in combination of TAT sequence. Braftide can be used for cancer research .
    Braftide
  • HY-101098
    PD-1-IN-18

    		PD-1/PD-L1 Inflammation/Immunology
    PD-1-IN-18 is a PD1 signaling pathway inhibitor, which acts as an immunomodulator.
    PD-1-IN-18
  • HY-P99465
    Befovacimab

    BAY 1093884

    		 Thrombin Tissue Factor Pathway Inhibitor (TFPI) Cardiovascular Disease
    Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research .
    Befovacimab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: